School of Medicine
Showing 1-9 of 9 Results
Clinical Assistant Professor, Pathology
BioDr. Joshua Menke completed his hematopathology fellowship at Stanford and cytopathology fellowship at University of California San Francisco (UCSF). His clinical and research interests lie at the intersection of hematopathology, cytopathology and advanced single cell and cell free diagnostic techniques. As Associate Director of the Flow Cytometry lab at Stanford, Dr. Menke will be developing and validating new minimal residual disease assays for detecting low levels of hematopoietic and lymphoid neoplasms in the post-treatment setting. Dr. Menke is the receipient of the Paul E. Standjord Young Investigator Award from the Academy of Clinical Laboratory Scientists and Laurance J. Marton Award for Excellence in Research from UCSF for his translational work on CALR mutations at the UCSF Molecular Diagnostics Laboroatory. Currently, he is spearheading novel genomic and proteomic analytic techniques to study cytology samples obtained for lymphoma diagnostics, including sequencing cell-free tumor DNA from supernatant samples. Dr. Menke is a founding member of the Cytology-Hematopathology Interinstitution Collaboration (CHIC) that aims to study the performance of cytology samples in diagnosing lymphoma across large datasets from five academic institutions.
Professor of Pathology (Research), Emerita
Current Research and Scholarly InterestsLymphocyte/endothelial cell adhesion mechanisms involved in lymphocyte migration to sites of inflammation; regulation of expression of endothelial cell adhesion molecules.
Paul Salomon Mischel
Professor of Pathology and, by courtesy, of Neurosurgery
Current Research and Scholarly InterestsMy research bridges cancer genetics, signal transduction and cellular metabolism as we aim to understand the molecular mechanisms that drive cancer development, progression, and drug resistance. We have made a series of discoveries that have identified a central role for ecDNA (extrachromosomal DNA) in cancer development, progression, accelerated tumor evolution and drug resistance.
Professor of Neurology and, by courtesy, of Neurosurgery, of Pediatrics, of Pathology and of Psychiatry and Behavioral Sciences
Current Research and Scholarly InterestsThe Monje Lab studies the molecular and cellular mechanisms of postnatal neurodevelopment. This includes microenvironmental influences on neural precursor cell fate choice in normal neurodevelopment and in disease states.
Stephen B. Montgomery
Associate Professor of Pathology, of Genetics, of Biomedical Data Science and, by courtesy, of Computer Science
Current Research and Scholarly InterestsWe focus on understanding the effects of genome variation on cellular phenotypes and cellular modeling of disease through genomic approaches such as next generation RNA sequencing in combination with developing and utilizing state-of-the-art bioinformatics and statistical genetics approaches. See our website at http://montgomerylab.stanford.edu/
Thomas Montine, MD, PhD
Stanford Medicine Professor of Pathology
BioDr. Montine received his education at Columbia University (BA in Chemistry), the University of Rochester (PhD in Pharmacology), and McGill University (MD and CM). His postgraduate medical training was at Duke University, and he was junior faculty at Vanderbilt University where he was awarded the Thorne Professorship in Pathology. In 2002, Dr. Montine was appointed as the Alvord Endowed Professor in Neuropathology and Director of the Division of Neuropathology at the University of Washington. He was Director of the University of Washington Alzheimer’s Disease Research Center, one of the original 10 Centers in the US, and passed that responsibility to able colleagues. In 2010, Dr. Montine was appointed Chair of the Department of Pathology at the University of Washington. In 2016, Dr. Montine was appointed Chair of the Department of Pathology at Stanford University where he is the Stanford Medicine Endowed Professor in Pathology.
Dr. Montine is the founding Director of the Pacific Udall Center, one of 9 NINDS-funded Morris K. Udall Centers of Excellence for Parkinson’s Disease Research. Our center performs basic, translational, and clinical research focused on cognitive impairment in Parkinson’s disease. The Pacific Udall Center emphasizes a vision for precision health that comprises functional genomics, development of surveillance tools for pre-clinical detection, and discovery of molecularly tailored therapies.
Dr. Montine is among the top recipients of NIH funding for all Department of Pathology faculty in the United States. He was the 2015 President of the American Association of Neuropathologists, and led or co-led recent NIH initiatives to revise diagnostic guidelines for Alzheimer’s disease (NIA), develop research priorities for the National Alzheimer’s Plan (NINDS and NIA), and develop research priorities for Parkinson’s Disease (NINDS).
The focus of the Montine Laboratory is on the structural and molecular bases of cognitive impairment with the goal of defining key pathogenic steps and thereby new therapeutic targets. The Montine Laboratory addresses these prevalent, unmet medical needs through a combination of neuropathology, biomarker development and application early in the course of disease, and experimental studies that test hypotheses concerning specific mechanisms of neuron injury and approaches to neuroprotection. PubMed lists 579 publications for Dr. Montine. Google Scholar estimates Dr. Montine’s citations as > 38,000, his i-10 index as 355, and his H-Index as 98. NIH iCite calculates (1995 to 2017) Dr. Montine’s weighted relative citation ratio as 2041.